Abstract
* Nivolumab (Opdivo) is now approved to treat advanced renal cell cancer in patients who have already received antiangiogenic therapy.
* The drug has the potential to cause serious immune-mediated effects, such as pneumonitis, colitis, hepatitis, endocrinopathies, nephritis and renal dysfunction, rash, and encephalitis.